Algernon Pharmaceuticals Company
Breathtec Biomedicala medical diagnostics company focused on developing, in-licensing, and commercializing proprietary innovative. Breathtec Biomedical (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Their efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung and breast cancers, neurodegenerative diseases like Alzheimer's, Parkinson's, tuberculosis, diabetes, liver disease, and more.
Technology:
COVID
Industry:
P4 Medicine
Headquarters:
Delta, Ontario, Canada
Zip:
1-10
Founded Date:
2015-01-01
Employees Number:
1-10
Funding Status:
N/A
Acquisitions Number:
2
Investors Number:
11457468
Total Funding:
$1M to $10M
Estimated Revenue:
2018-02-19
Last Funding Date:
Post-IPO Equity
Last Funding Type:
info@breathtecbiomedical.com
Register and Claim Ownership